Gilead Sciences (GILD) boasting a 92 billion dollar market Amphotericin B drug has been already in use for more than 50 years by such companies as Gilead Sciences (GILD) boasting a 92 billion dollar market cap
Amphotericin B generated a revenue 0f $621 million - fourth quarter of 2016
PROBLEM = administered via intravenous or injection in Patients in Hospital
ICO ORAL B is the same drug (GILDamphotericin B ) but cusrrently being tested using their patented Oral Products. This is a FIRST and Exclusive methodology. This New Drug Form will streamline patient use with convenient at home personal medication being made possible. Millions of dollars in hospital costs and Doctor fees will be saved by using ORAL B in this new oral fashion rather than injection.
Question is, why would anyone continue using current methods of dosing?
ICO is about to KIDNAP a HUGE established market with this new research!